GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in patients with multiple myeloma at or after first relapse.

UK pharma major GSK on Friday announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Blenrep (belantamab mafodotin) in combinations with bortezomib plus ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

It affects the immunity-boosting white blood cells. GSK expects peak annual sales for Blenrep, chemically called belantamab mafodotin, of over 3 billion pounds ($3.97 billion). The drug is ...

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Today’s approval of Blenrep combinations in the UK is a transformative milestone for patients with multiple myeloma, a ...